• Non ci sono risultati.

CURRICULUM VITAE OF VENERINO POLETTI ACTUAL POSITION EDUCATION PROFESSIONAL POSITIONS

N/A
N/A
Protected

Academic year: 2022

Condividi "CURRICULUM VITAE OF VENERINO POLETTI ACTUAL POSITION EDUCATION PROFESSIONAL POSITIONS"

Copied!
8
0
0

Testo completo

(1)

CURRICULUM VITAE OF VENERINO POLETTI

Born on 28 December 1956 in Bagnacavallo (RA)

ACTUAL POSITION

- Principal of department of thoracic and lung diseases, USL of Romagna

EDUCATION

1981: Medicai School, 110/110 with honours, University of Bologna

1985: Postdoctoral in respiratQry medicine and lung diseases, 70/70 with honours 1989: Postdoctoral in Pathological anatomy, 70/70 with honours

PROFESSIONAL POSITIONS

November 2001 - present: Principal of pneumology unit and thoracic endoscopy, G.B. Morgagni Hospital, Forlì, Italy.

June 2010 - present: Principal of pneumology unit, G.B. Morgagni Hospital, Forlì, Italy.

October 2015 - present: Principal of department of thoracic and lung diseases, USL of Romagna.

Aprii 2018 - present: Principal of pneumology unit, Lugo (Ravenna), Italy.

TEACHING ACTIVITIES

1. Professor to respiratory medicine postdoctoral school, University of Bologna, from 1991 to 1996.

2. Professor to respiratory medicine postdoctoral school, University of Parma, from 1994 to 2014.

3. Guest lecturer to speech therapy and lung diseases degree cour:se, University of Bologna, from 2007 to 2012.

4. Professor to Master of Pneumology, University of Florence, 2010-2011 5. Laerestolsrofessor, Aarhus University, Denmark, 2015- present.

STUDY MISSIONS

November 1987: Study mission ta Division of Anatomie Pathology, Brompton Hospital, London.

(2)

November/December 1992 :Study mission to Department of Pathology and Microbiology, University Medicai Center, Omaha, Nebraska.

December 1993: Study mission to Department of Pathology and Microbiology, University Medicai Center

December 1996: Study mission to Department of Anatomie Pathology, Maya Clinic, Rochester.

December 1999: Study mission to Ruhrland Klinik, Essen, Germany.

PARTECIPATIONS IN SCIENTIFIC SOCIETIES

- American College of Chest Physicians, FCCP, from 1987 - Italian Association of Clinica! Pneumologists from 1991

- Italian Association of Respiratory Medicine (SIMER) from 2000 - European Respiratory Society from 1993

- Officer of ERS from 2008

- American Thoracic Society from 1993 to 2010

- World Association of Sarcoidosis and Other Granulomatous Lung from 1999 - Pulmonary Pathology Society from 1999

- European Association of Bronchology from 2003

SCIENTIFIC AND REGULATORV ACTIVITIES

- Clinica! member of Reviewer Panel on "ATS/ERS International multidisciplinary Consensus Classification of the idiopathic interstitial pneumonias". Results are published on American Journal of Respiratory and Criticai Care Medicine" and on

"European Respiratory Journal" [2002].

- Member of "Core panel" built in association with the American Thoracic Society and European Respiratory Society, far the reclassification of "Smoking relateci Lung Diseases".

Secretary of Group 1.5 "Diffuse Parenchymal Lung Diseases" of European Respiratory Society [March 2008-2011] ·

- Chairman of Group 1.5 "Diffuse Parenchymal Lung Diseases" of European Respiratory Society [March 2011- September 2014]

- Secretary of Clinica! Assembly, European Respiratory Society [From September 2015 to present]

- Member of Council of European Respiratory Society [2012 to present]

RESEARCH AREAS

- Diffuse infiltrative pulmonary diseases (IPF, Sarcoidosis, Extrinsic Allergie Alveolitis, Organizing Pneumonia, etc.).

(3)

- Pathogenesis of IPF .

- Pulmonary complications in immunosuppressed subjects (expecially haematologics and HIV positives).

- Hystopathology/cytopathology, immunohistochemistry, and molecular biology of non neoplastc and neoplastic pulmonary diseases.

- Interventional pneumology (Bronchoalveolar lavage, transbronchial biopsies, EBUS-EUS, cryobiopsy, therapeutic bronchology, ... ).

- Pulmonary neoplasms

EDITORIAL WORK

Member of Editoria! Committee of "Newsletter of Respiratory Pathology" (1999 to present).

- Member of Scientific committee of Medicine Academy, section "Respiratory Diseases" (2003-2013).

- Member of Editoria I Board of "Sarcoidosis Vasculitis Diffuse Lung Diseases"

(2002 -2008).

- Associate Editor of "Sarcoidosis Vasculitis Diffuse Lung Diseases" (2008 -2012).

- Editor of "Case report-session" of Sarcoidosis Vasculitis Diffuse Lung Diseases (2009-2012).

- Editor in Chief Sarcoidosis Vasculitis Diffusae Lung Diseases (2012 -present).

- Member of "World Journal of gastrointestinal Endoscopy" (2010-2014)

- Member of International Editoria! Board of "Pneumology I Alergologia Polska"

(2014-present)

- Member of Editoria I Board of "Journal of Respiratory Research" (2015-present).

- Member of Editoria I Boarçl of "Rivista Portugueasa de Pneumologia" "2015- present)

- Asso:çig;te ,Editor, "Breath'', (2015-present)

- Member of Editoria! Board "Respiration", (2016-present).

PRINTED S'CIENTIFIC PUBLICATIONS

- 122 publications not quoted on PubMed

(4)

- 238 pubblications quated on PubMed - 8 books/CD Rom

- 17 sections in internatiional textbooks of respiratory diseases.

BIBLIOMETRICS INDICATORS

- Google Scholar 2017: H-index = 43 - Publish or Perish 2017: H-index = 43

Scopus 2017: H Index = 37

Researchgate H Index=37 ; 35 excluding self-citations - IMPACT FACTOR TOTALE =864,129

- IMPACT FACTOR MEDIO=3,63

- • Citations Total=6992 (Scopus); 10735 (Google Scholar)

Native language: Italian English: Cl

French: Al

LANGUAGE SKILLS

(5)

Appendice 15

MODELLO DI DICHIARAZIONE PUBBLICA SUL CONFLITTO DI JNTERESSI DELLO SPERIMENTATORE

Nome (stampatello) Cognome (stampatello) Qualifica

V

ener1no ... .

.

Poletti. ... . Professore ... . Ente di appartenenza Ospedale Morgagni - Pierantoni ... .

Impiego nell'industria farmaceutica nel corso degli ultimi cinque anni 1:

Elencare ogni eventuale interesse nel! 'industria farmace tica (se necessario, utilizzare più moduli)

• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • ! • • • ' ' • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • · • • • • • • • • • • • ! • • • • • • • • • • • • • • • • • • • • • • • • • •

···~--··· ...

·

... .

Interessi finanziari nel capitale di un'industria farmaceu ··a:

Nome dell'industria: ... ... . Tipo di azioni: ••••••••••r•••••••••••••••••• •••••••••••••••••••••••••••••••••••••••••••••••••••••••••

Numero di azioni: ••••••••••••••••••••••••• •••••••••••••••••••••••••••••••••••••••••••••••o•••••••••••

Altri rapporti con l'industria farmaceutica2: /

::::::::::::::::::::::::::::::::::::::::::::::;<::::::::·::::~::::::::::::::::::::::::::::::::::::::::::::::::::::::

•••••••••••••••••••••••••••••••••••••••••:•••••••••• ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••

···"··· ···,···

Altri interessi o fatti che si ritiene debbano essere portati a conoscenza, ivi compresi elementi relativi ai componenti del proprio nucleo familiare (i componenti del nucleo familiare sono: il coniuge, il/la compagno/a e i figli a carico che vivono sotto lo stesso tetto dell'interessato):

(non è necessario menzionare il nome di tali persone

...

,

...

,

... .

···-···

···•·,(••··· ... .

Tutte le attività svolte (direttamente o indirettatnente) per le ditte farmaceutiche (o per loro conto; in questo caso, specificare il proprio ruolo e le attività svolte e indicare il nome del prodotto e la natura del lavoro svolto), sia che tali attività abbiano comportato o meno remunerazione regolare od occasionale, in denaro oppure in natura, fra le quali:

" partecipazione al processo decisionale all'interno di una ditta farmaceutica (per es., partecipazione al consiglio di amministrazione, direzione esecutiva o non esecutiva);

• appartenenza permanente o temporanea al personale di una ditta farmaceutica. Altre attività svolte all'interno di una ditta farmaceutica (per es., tirocinio) sono ugualmeµte soggette a dichiarazione;

lavoro di consulenza o di altro genere, appaltato da ditte farmaceutiche.

2 Ogni tipo di assistenza e sostegno ricevuto dalliindustria durante i precedenti 5 anni, comprendente o meno benefici pecuniari o materiali, diretti o indiretti, del tipo: borse di studio o di ricerca istituite dall'industria,jèllowship o sponsorizzazioni sovvenzionate dall'industria farmaceutica.

pag. 1 di 2

(6)

- Appendice 15 -

Il/la sottoscritto/a dichiara di non detenere, a sua conoscenza, altri interessi diretti o indiretti•

nell'industria farmaceutica oltre a quelli summenzionati.

Dichiara inoltre che si impegna a presentare una nuova dichiarazione pubblica di interessi qualora dovessero risultare nuovi o ulteriori interessi, tali dal dover essere portati a conoscenza.

1tf / 12

/Zo

1S

Data ... .

pag. 2 di2

(7)

Sponsor: Respivant Sciences, lnc.

Protocol lD/Number: RVT1601-CC-04

Informazioni sulle strutture coinvoJte nello studio

Con la presente il sottoscritto __ P_r_of_._v_e_n_e_ri_n_o_P_o_l_et_ti __

in qualità di Sperimentatore Principale, dichiara che, per lo svolgimento della suddetta Sperimentazione presso

U.O. Pneumologia Interventistica, Ospedale G.B. Morgagni - L.Pierantoni saranno coinvolte le seguenti strutture.:

U.O. Pneumologia Interventistica, Ospedale G.B. Morgagni - L.Pierantoni

Data

18 (1Z/

ZCJ//2

(8)

Sponsor: Respivant Sciences, lnc.

Protocol ID/Number: RVT1601-CC-04

Informazioni sul personale ausiliario studio:

Con la presente il sottoscritto __ P_ro_f_. V_en_e_r1_· n_o_P_o_le_tt_i __

in qualità di Sperimentatore Principale, dichiara che, per lo svolgimento della suddetta Sperrimentazione presso

U.O. Pneumologia Interventistica, Ospedale G.B. Morgagni-L.Pierantoni saranno coinvolte le seguenti figure professionali:

Dott.ssa Sara Tomassetti (SI)

Dott.ssa Silvia Puglisi (SI)

Dott.ssa Antonella Arcadu (SI)

Dott. Luca Donati (SC)

Brunella Biondi (Study Nurse)

Marco Benini (Respiratory Technician)

Data

-11 /1z ( lof'$

Firma

)

sfo

RA- P, e I c1

O---H I

(f..frf)k:>C:e:,w

sr)

V/ f\J Cl:::J02o Y( r;._~E7'7ì4--

(t1-t1-1v-t+e-1.S7Y

Riferimenti

Documenti correlati

From Knightian to Keynesian Uncertainty: Contextualizing the Ellsberg Paradox, paper presented at the HES Meeting, Chicago, June 2018, submitted to Cambridge Journal of Economics

Development of local approaches for fatigue life prediction of Austempered Ductile Iron-to-Steel dissimilar joints 6.16 S-N curve of full-penetration ground butt-joints

In this work, 316L stainless steel samples made with additive manufactur- ing powder bed fusion technology, have been characterized; focus has been given to laser power and to

The features used for the attack and the defense model is only obtained by RSS channel model that use A+S, because the defense models that used RSS channel model with A+S+F are

• Dijkstra’s algorithm for the global navigation, that is used for compute the path from the current position and the local goal.. The local goal is selected using a greedy

• Length of segment between 15 and 60 seconds, normally used 30-second intervals As last point, we observe the power spectrum of the neural signals in these segments and we

It is recent news that the “New Guidelines for internal architectures in schools” (Italian Ministerial Decree April 11 th 2013) have been approved, whose inspiration is drawn from

Indeed, in order to evaluate if iPA could be a useful agent able to inhibit tumor angiogenesis, we tested in vitro the ability of iPA to arrest the proliferation and